Navigation Links
Perrigo Settles Desloratadine Patent Litigation
Date:12/4/2008

ALLEGAN, Mich., Dec. 4 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all relevant patents. Perrigo had been sued for patent infringement of US Patent Nos. 6100274, 7214683 and 7214684 based upon its filing of an ANDA containing a Paragraph IV certification. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Perrigo product is awaiting FDA approval.

This product seeks an AB-rating as equivalent to Schering-Plough's Clarinex(R) tablets (5 mg) indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Sales for the brand were approximately $300 million, according to Wolters Kluwer data for the twelve months ending October 2008.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued commitment to bring new products to the market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom.
'/>"/>

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
2. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
3. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
4. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
5. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
6. Perrigo Company Announces Appointment of New Board Member
7. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
8. Perrigo Announces Approval for Rx Cetirizine Syrup
9. Perrigo Confirms Filing for Generic Version of VANOS(R)
10. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
11. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Nike Swim Camps offer outstanding coaching by ... to stimulate a love of swimming in a positive ... the opportunity to train with some of the most ... President of US Sports Camps. “Our program directors provide ... confidence and improve their technique.” , Nike Swim Camp ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... therapeutics market is driven by the increasing incidence of ... encouraging pipeline of late stage drugs. The unmet medical ... fore the untapped potential in the market. Presently, there ... drugs that overcome the limitations of current generation drugs. ...
(Date:3/4/2015)... Ohio (PRWEB) March 04, 2015 Nitrosigine®, ... an ingredient in premium sports nutrition products, is hosting ... Trainer booth in the Terrace Ballroom at The Arnold ... from March 5, 2015 to March 8, 2015. ... silicate with FDA New Dietary Ingredient notification status; now ...
(Date:3/4/2015)... 2015 Follow us on LinkedIn ... the appearance of the skin and body, are witnessing ... therapeutic agents to achieve the desired product properties and ... obsessed with physical beauty, youth, and achievement. Demand for ... sales of cosmetics. Growth in the market is driven ...
(Date:3/4/2015)... The report “Vasculitis – Pipeline Review, ... for Vasculitis. Vasculitis is a disease that features tenderness ... diseases is not known. Vasculitis can affect any body ... Symptoms can include fever, weight loss, tiredness, aches, pains, ... a limb. Vasculitis is treatable, but it is not ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Swim Camps Announce the 2015 Swim Camps Lineup 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4
... University of Utah researchers in the development and testing of ... would transmit the nerve impulses from nerves in the residual ... then to the bionic arm. This will facilitate the person ... ,Sensors placed in the artificial arm will be designed ...
... ocean currents in climate change and the story behind Antarctica’s ... to be holding the clue. ,An element pretty ... teeth has offered a clue to the University of Florida ... Atlantic and Pacific might have opened up. This has happened ...
... Administration is being prompted by the Drug Manufacturer, Wyeth ... hormone drugs to treat menopause.// The drugs are made ... approved. ,Following Wyeth's recommendation to the FDA, the ... on these custom-made treatments, and have requested the agency ...
... Functional and structural difference in the brain can explain ... in unique ways to the effects// of certain pain-relief ... Georgia State University and the Atlanta-based Center for Behavioral ... conducted on rat brains, the results highlight that similar ...
... a report by the Food and Agriculture Organisation (FAO) of ... animal species said that domestic and wild birds spread the ... accumulated since the start of the avian influenza crisis (the ... in the transmission of the virus in the natural setting. ...
... and as a clean up drive legalisation of drugs is ... free drugs to addicts// to help clean up the Downtown ... Sam Sullivan a donation by an anonymous donor of $500,000 ... ,The reason and goal behind this whole exercise would be ...
Cached Medicine News:Health News:Gender Difference In Pain Experience Explained By Brain Diversity 2
(Date:3/4/2015)... , March 4, 2015   Mallinckrodt ... biopharmaceutical company, will present at the Barclays Global Healthcare ... Miami, Florida , on Wednesday, March 11, 2015. Mark ... represent the company in a session scheduled to begin ... attend the meeting in person can find webcast information ...
(Date:3/4/2015)...   Symbiomix Therapeutics , a late-stage, privately ... women,s health infections, today announced results from its ... product candidate, SYM-1219, was safe and well tolerated ... efficacy for birth control pills would not be ... will be presented on March 6 th ...
(Date:3/3/2015)... -- Actavis plc (NYSE: ACT ) today ... billion aggregate principal amount of senior unsecured notes in ... issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, ... "Notes"), as follows: Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... $500,000,000 , Due 2016 , 100.00% 1.850% ...
Breaking Medicine Technology:Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... and live webcast on Wednesday, November 2, 2011 at 9:00 ... The Company will release its financial results on November 2, ... live webcast can be made via the Company,s website at ...
... 2011 The Infectious Disease Research Institute (IDRI) announces ... broad range of instrumentation and equipment that will assist ... the burden of disease in the developing world. IDRI ... trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, ...
Cached Medicine Technology:GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: